NIKKEI 225
37,143.00 -936.70 (-2.46%) HANG SENG
16,184.02 -201.85 (-1.23%) CRUDE OIL
84.25 +1.52 (+1.84%) GOLD FUTURES
2,398.30 +0.30 (+0.01%) DOW
37,775.38 +22.07 (+0.06%) Bitcoin GBP
50,302.30 +641.25 (+1.29%)
Medigene AG (0QGJ.L)
- GlobeNewswire
Medigene to Present at Upcoming Scientific Conferences
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been invited to present at the CHI's 8th Annual Immuno-Oncology Summit Europe from April 23-25, 2024, in London, UK, as well as at the 7th International Neoantigen Summit to be held in Amsterdam, Netherlands from April 29 - May 1, 2024. The presentations will be available on Medigene´s website after the c
- GlobeNewswire
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today presents superior recombinant T cell receptor (rTCR) engineered T cell functionality as well as a favorable safety profile when rTCR-T cells are armored and enhanced with the PD1-41BB costimulatory switch protein (CSP) at the American Association for Cancer Research (
- Globe Newswire
Medigene AG Secures European Patent for its iM-TCR Technology
Planegg/Martinsried, April 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor (iM-TCR) technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell (TCR-T) therapie
